Skip to main content

Advertisement

SpringerLink
Log in

Can hyperbaric oxygenation decrease doxorubicin hepatotoxicity and improve regeneration in the injured liver?

  • Original article
  • Published:
Journal of Hepato-Biliary-Pancreatic Surgery

Abstract

Background/Purpose

Portal vein embolization is used in the treatment of hepatocellular cancer, with the purpose of enhancing resectability. However, regeneration is restricted due to hepatocellular injury following chemotherapeutics (e.g. doxorubicin). The aim of this study was to investigate whether hyperbaric oxygenation (HBO) can alleviate the hepatotoxicity of chemotherapy and improve regeneration in the injured liver.

Methods

Rats were allocated to four experimental groups. Group I rats were subjected to right portal vein ligation (RPVL); rats in groups II and III were administered doxorubicin prior to RPVL, with group III rats being additionally exposed to HBO sessions postoperatively; group IV rats was sham-operated. All rats were sacrificed on postoperative day 7, and liver injury was assessed by measuring alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Protein synthetic ability was determined based albumin levels and liver regeneration by the mitotic index (MI).

Results

The AST and ALT values of group II rats were significantly higher than those of group I, but not those of group III. Rats treated with doxorubicin and HBO (groups II and III) showed slightly but not significant differences in albumin levels than those subjected to only RPVL or sham-operated. The MI was significantly increased in groups I, II, and III, with the MI of group III rats significantly higher than those of group I rats.

Conclusions

Based on our results, we conclude that HBO treatment has the potential to diminish doxorubicin-related hepatotoxicity and improve regeneration in the injured liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bosch F. Global epidemiology of hepatocellular carcinoma. In: Tabor E, ed. Liver cancer. New York: Churchill Livingstone; 1997. p. 13–28.

    Google Scholar 

  2. Sotiropoulos GC, Lang H, Frilling A, Molmenti EP, Paul A, Nadalin S, et al. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature. Hepatogastroenterology. 2006;53:322–9.

    PubMed  Google Scholar 

  3. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237:686–91. (discussion 691–3).

    Article  PubMed  Google Scholar 

  4. Takayama T, Makuuchi M. Preoperative portal vein embolization: is it useful? J Hepatobiliary Pancreat Surg. 2004;11:17–20.

    Article  PubMed  Google Scholar 

  5. Belghiti J. Arguments for a selective approach of preoperative portal vein embolization before major hepatic resection. J Hepatobiliary Pancreat Surg. 2004;11:21–4.

    Article  PubMed  Google Scholar 

  6. Chik BH, Liu CL, Fan ST, Lo CM, Poon RT, Lam CM, et al. Tumor size and operative risks of extended right-sided hepatic resection for hepatocellular carcinoma: implication for preoperative portal vein embolization. Arch Surg. 2007;142:63–9. discussion 69.

    Article  PubMed  Google Scholar 

  7. Koren G, Beatty K, Seto A, Einarson TR, Lishner M. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother. 1992;26:363–71.

    PubMed  CAS  Google Scholar 

  8. Bagchi D, Bagchi M, Hassoun EA, Kelly J, Stohs SJ. Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology. 1995;95:1–9.

    Article  PubMed  CAS  Google Scholar 

  9. Soderdahl G, Backman L, Isoniemi H, Cahlin C, Hockerstedt K, Broome U, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int. 2006;19:288–94.

    Article  PubMed  CAS  Google Scholar 

  10. Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant. 2005;5(4 Pt 1):788–94.

    Article  PubMed  CAS  Google Scholar 

  11. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532–8.

    Article  PubMed  CAS  Google Scholar 

  12. McDonald GB, Tirumali N. Intestinal and liver toxicity of antineoplastic drugs. West J Med. 1984;140:250–9.

    PubMed  CAS  Google Scholar 

  13. Yagmurca M, Bas O, Mollaoglu H, Sahin O, Nacar A, Karaman O, et al. Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch Med Res. 2007;38:380–5.

    Article  PubMed  CAS  Google Scholar 

  14. Kalender Y, Yel M, Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology. 2005;209:39–45.

    Article  PubMed  CAS  Google Scholar 

  15. Uwagawa T, Unemura Y, Yamazaki Y. Hyperbaric oxygenation after portal vein emobilization for regeneration of the predicted remnant liver. J Surg Res. 2001;100:63–8.

    Article  PubMed  CAS  Google Scholar 

  16. Nagamine K, Kubota T, Togo S, Nagashima Y, Mori M, Shimada H. Beneficial effect of hyperbaric oxygen therapy on liver regeneration after 90% hepatectomy in rats. Eur Surg Res. 2004;36:350–6.

    Article  PubMed  CAS  Google Scholar 

  17. Ozden TA, Uzun H, Bohloli M, Toklu AS, Paksoy M, Simsek G, et al. The effects of hyperbaric oxygen treatment on oxidant and antioxidants levels during liver regeneration in rats. Tohoku J Exp Med. 2004;203:253–65.

    Article  PubMed  CAS  Google Scholar 

  18. Kurir TT, Markotic A, Katalinic V, Bozanic D, Cikes V, Zemunik T, et al. Effect of hyperbaric oxygenation on the regeneration of the liver after partial hepatectomy in rats. Braz J Med Biol Res. 2004;37:1231–7.

    Article  PubMed  CAS  Google Scholar 

  19. Tolentino EC, Castro e Silva O, Zucoloto S, Souza ME, Gomes MC, Sankarankutty AK, et al. Effect of hyperbaric oxygen on liver regeneration in a rat model. Transplant Proc. 2006;38:1947–52.

    Article  PubMed  CAS  Google Scholar 

  20. Ijichi H, Taketomi A, Yoshizumi T, Uchiyama H, Yonemura Y, Soejima Y, et al. Hyperbaric oxygen induces vascular endothelial growth factor and reduces liver injury in regenerating rat liver after partial hepatectomy. J Hepatol. 2006;45:28–34.

    Article  PubMed  CAS  Google Scholar 

  21. Ozdogan M, Ersoy E, Dundar K, Albayrak L, Devay S, Gundogdu H. Beneficial effect of hyperbaric oxygenation on liver regeneration in cirrhosis. J Surg Res. 2005;129:260–4.

    Article  PubMed  CAS  Google Scholar 

  22. Kaelin CM, Im MJ, Myers RA, Manson PN, Hoopes JE. The effects of hyperbaric oxygen on free flaps in rats. Arch Surg. 1990;125:607–9.

    PubMed  CAS  Google Scholar 

  23. Aydinoz S, Uzun G, Cermik H, Atasoyu EM, Yildiz S, Karagoz B, et al. Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity. Ren Fail. 2007;29:257–63.

    Article  PubMed  CAS  Google Scholar 

  24. Kulik LM. Advancements in hepatocellular carcinoma. Curr Opin Gastroenterol. 2007;23:268–74.

    Article  PubMed  Google Scholar 

  25. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 2002;3:593–603.

    Article  PubMed  Google Scholar 

  26. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg. 2003;238:508–18. discussion 518–9.

    Article  PubMed  Google Scholar 

  27. Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231:480–6.

    Article  PubMed  CAS  Google Scholar 

  28. Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000;127:512–9.

    Article  PubMed  CAS  Google Scholar 

  29. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26:1176–81.

    PubMed  CAS  Google Scholar 

  30. Elias D, Ouellet JF, De Baère T, Lasser P, Roche A. Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival. Surgery. 2002;131:294–9.

    Article  PubMed  Google Scholar 

  31. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57. discussion 657–8.

    Article  PubMed  Google Scholar 

  32. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004;240:1037–49. discussion 1049–51.

    Article  PubMed  Google Scholar 

  33. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237:208–17.

    Article  PubMed  Google Scholar 

  34. Elias D, Debaere T, Roche A, Bonvallot S, Lasser P. Preoperative selective portal vein embolizations are an effective means of extending the indications of major hepatectomy in the normal and injured liver. Hepatogastroenterology. 1998;45:170–7.

    PubMed  CAS  Google Scholar 

  35. Kwiecien M, Michalska I, Wlodek L. The selective effect of cystathionine on doxorubicin hepatotoxicity in tumor-bearing mice. Eur J Pharmacol. 2006;550:39–46.

    Article  PubMed  CAS  Google Scholar 

  36. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6(2):162–76.

    Article  PubMed  CAS  Google Scholar 

  37. Marchand DJ, Renton KW. Depression of cytochrome P-450-dependent drug biotransformation by adriamycin. Toxicol Appl Pharmacol. 1981;58:83–8.

    Article  PubMed  CAS  Google Scholar 

  38. Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 2001;21:469–73.

    Article  PubMed  CAS  Google Scholar 

  39. Hampson NB, ed. Hyperbaric Oxygen Therapy: 1999 Committee report. Kensington MD, Undersea and Hyperbaric Medical Society, 1999.

  40. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med. 1996;334:1642–8.

    Article  PubMed  CAS  Google Scholar 

  41. Gill AL, Bell CN. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM. 2004;97:385–95.

    Article  PubMed  CAS  Google Scholar 

  42. Mazariegos GV, O’Toole K, Mieles LA, Dvorchik I, Meza MP, Briassoulis G, et al. Hyperbaric oxygen therapy for hepatic artery thrombosis after liver transplantation in children. Liver Transpl Surg. 1999;5:429–36.

    Article  PubMed  CAS  Google Scholar 

  43. Grover I, Conley L, Alzate G, Lavine J, Van Hoesen K, Khanna A. Hyperbaric oxygen therapy for hepatic artery thrombosis following liver transplantation: current concepts. Pediatr Transplant. 2006;10:234–9.

    Article  PubMed  Google Scholar 

  44. Castro e Silva O, Sankarankutty AK, Martinelli AL, Souza FF, Teixeira AC, Feres O, et al. Therapeutic effect of hyperbaric oxygen in hepatic artery thrombosis and functional cholestasis after orthotopic liver transplantation. Transplant Proc. 2006;38:1913–7.

    Article  PubMed  Google Scholar 

  45. Asanuma Y, Sato T, Yasui O, Kurokawa T, Koyama K. Treatment for postoperative liver failure after major hepatectomy under hepatic total vascular exclusion. J Artif Organs. 2003;6:152–6.

    PubMed  Google Scholar 

  46. Ponikvar R, Buturović J, Cizman M, Mekjavić I, Kandus A, Premru V, et al. Hyperbaric oxygenation, plasma exchange, and hemodialysis for treatment of acute liver failure in a 3-year-old child. Artif Organs. 1998;22:952–7.

    Article  PubMed  CAS  Google Scholar 

  47. Feldmeier J, Carl U, Hartmann K, Sminia P. Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea Hyperb Med. 2003;30:1–18.

    PubMed  CAS  Google Scholar 

  48. Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y, et al. Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg. 2000;17:42–8.

    Article  PubMed  CAS  Google Scholar 

  49. Yoshioka S, Miyazaki M, Shimizu H, Ito H, Nakagawa K, Ambiru S, et al. Hepatic venous hemoglobin oxygen saturation predicts regenerative status of remnant liver after partial hepatectomy in rats. Hepatology. 1998;27:1349–53.

    Article  PubMed  CAS  Google Scholar 

  50. Petre PM, Baciewicz FA Jr, Tigan S, Spears JR. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model. J Thorac Cardiovasc Surg. 2003;125:85–95. (discussion 95).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, Ege University Hospital, 3rd Floor, Bornova, 35100, Izmir, Turkey

    Ozgur Firat, Ozer Makay, Cemil Caliskan, Ahmet Coker & Murat Zeytunlu

  2. Department of General Surgery, Tepecik Education and Research Hospital, Izmir, Turkey

    Ozgur Kirdok

  3. Department of Pathology, Ege University Hospital, Izmir, Turkey

    Funda Yilmaz

  4. Neoks Hyperbaric Treatment Center, Izmir, Turkey

    Savas Ilgezdi

  5. Department of Medical Oncology, Ege University Hospital, Izmir, Turkey

    Bulent Karabulut

Authors
  1. Ozgur Firat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozgur Kirdok
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ozer Makay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cemil Caliskan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Funda Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Savas Ilgezdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bulent Karabulut
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ahmet Coker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Murat Zeytunlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ozgur Firat.

About this article

Cite this article

Firat, O., Kirdok, O., Makay, O. et al. Can hyperbaric oxygenation decrease doxorubicin hepatotoxicity and improve regeneration in the injured liver?. J Hepatobiliary Pancreat Surg 16, 346–352 (2009). https://doi.org/10.1007/s00534-009-0059-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00534-009-0059-9

Keywords

Search

Navigation